Skip to content

Clinical Evaluation Research for Shenqi Sequential Therapy in the Prevention and Treatment of Macrovascular Disease in Type 2 Diabetes

Clinical Evaluation Research for Shenqi Sequential Therapy in the Prevention and Treatment of Macrovascular Disease in Type 2 Diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018410
Enrollment
Unknown
Registered
2018-09-16
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macrovascular Disease in Type 2 Diabetes

Interventions

Sponsors

Teaching Hostital of Chengdu university of T.C.M
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) The patient who is Voluntary to participate in this study, and sign the informed consent; (2) Aged 18 to 70 years; (3) In accordance with the diagnostic criteria of type 2 diabetes mellitus and meet the diagnostic criteria of TCM syndrome of deficiency, phlegm,or stasis; (4) Type 2 diabetic patients of glycosylated hemoglobin is less than 7%.

Exclusion criteria

Exclusion criteria: (1) With a serious heart, brain, liver, kidney, blood hematopoietic system of primary diseases and psychosis patients; (2) Acute diabetes complications, including diabetic ketoacidosis, diabetes, high permeability of ketosis coma, hypoglycemia coma or severe unconsciousness hypoglycemia, etc; (3) Pregnant or lactating women; (4) suffering from severe infections within 1 month; (5) People who are using insulin, aspirin(>300mg/d), PPAR-alpha ligands, PPAR-gama ligands; (6) Allergies or allergic reactions to drugs used in this study; (7) People who are uncooperative during the start-up stage; (8) people who have drug or other substance abuse or alcoholics.

Design outcomes

Primary

MeasureTime frame
CRP;TNF-a;FIB;Carotid atherosclerotic plaque;AGEs;Oxidative Stress Index;

Secondary

MeasureTime frame
Blood Glucose;HbA1c;Blood Lipid;Hemorheology;Coagulation function;

Countries

China

Contacts

Public ContactHong Gao

Chengdu University of Traditional Chiese Medicine

690155619@qq.com+86 13880622095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026